A Phase I Study of LXS196 in Patients With Metastatic Uveal Melanoma.
Status:
Active, not recruiting
Trial end date:
2022-06-02
Target enrollment:
Participant gender:
Summary
This study is to characterize the safety, tolerability, pharmacokinetics (PK),
pharmacodynamics (PD) and preliminary anti-tumor activity of LXS196 as a single agent and in
combination with HDM201 in patients with metastatic uveal melanoma.